We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-8.84%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$31.6M
AUM Growth
-$122M
Cap. Flow
-$117M
Cap. Flow %
-370.46%
Top 10 Hldgs %
73.58%
Holding
48
New
6
Increased
1
Reduced
11
Closed
29

Top Buys

Rank Stock Value
1
IMDX
Insight Molecular Diagnostics
IMDX
+$432K

Top Sells

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$6.06M
2
NTRA icon
Natera
NTRA
+$5.61M
3
ISRG icon
Intuitive Surgical
ISRG
+$5.31M
4
MSOS icon
AdvisorShares Pure US Cannabis ETF
MSOS
+$4.71M
5
BVS icon
Bioventus
BVS
+$4.17M

Sector Composition

Rank Sector Weight
1 Healthcare 48.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ESTA icon
1
Establishment Labs
ESTA
$2.33B
$5.21M 16.48%
113,041
-78,898
-41% -$3.44M
MSOS icon
2
AdvisorShares Pure US Cannabis ETF
MSOS
$880M
$2.86M 9.04%
750,000
-873,100
-54% -$4.71M
LUNG icon
3
Pulmonx
LUNG
$89.3M
$2.63M 8.32%
387,200
-122,575
-24% -$807K
QTRX icon
4
Quanterix
QTRX
$188M
$2.5M 7.9%
234,755
-115,946
-33% -$1.41M
ISRG icon
5
CALL
Intuitive Surgical
ISRG
$133B
$1.83M 5.78%
+3,500
New +$1.82M
GKOS icon
6
CALL
Glaukos
GKOS
$10.4B
$1.8M 5.69%
+12,000
New +$1.65M
PPH icon
7
PUT
VanEck Pharmaceutical ETF
PPH
$935M
$1.73M 5.46%
+20,000
New +$1.81M
NTRA icon
8
CALL
Natera
NTRA
$45B
$1.58M 5.01%
+10,000
New +$1.46M
BVS icon
9
CALL
Bioventus
BVS
$1.16B
$1.57M 4.98%
+150,000
New +$1.77M
IMDX
10
Insight Molecular Diagnostics
IMDX
$154M
$1.56M 4.93%
654,451
+159,106
+32% +$432K
ICUI icon
11
CALL
ICU Medical
ICUI
$4.54B
$1.55M 4.91%
10,000
-5,000
-33% -$846K
NSPR icon
12
InspireMD
NSPR
$33.7M
$1.18M 3.75%
450,517
IHI icon
13
PUT
iShares US Medical Devices ETF
IHI
$3.36B
$1.17M 3.69%
20,000
-130,000
-87% -$7.73M
MGX icon
14
Metagenomi Therapeutics
MGX
$46.7M
$954K 3.02%
264,391
-6,227
-2% -$15K
INMD icon
15
PUT
InMode
INMD
$875M
$835K 2.64%
50,000
-10,000
-17% -$177K
QTRX icon
16
CALL
Quanterix
QTRX
$188M
$797K 2.52%
+75,000
New +$912K
NTRA icon
17
Natera
NTRA
$45B
$792K 2.5%
5,000
-38,500
-89% -$5.61M
CSTL icon
18
CALL
Castle Biosciences
CSTL
$963M
$666K 2.11%
25,000
-25,000
-50% -$761K
CUTR
19
DELISTED
Cutera, Inc.
CUTR
$403K 1.27%
1,141,009
-24,488
-2% -$12.2K
ARKG icon
20
PUT
ARK Genomic Revolution ETF
ARKG
$1.7B
-75,000
Closed -$1.92M
BAX icon
21
CALL
Baxter International
BAX
$14.1B
-30,000
Closed -$1.14M
BRKR icon
22
Bruker
BRKR
$8.07B
-18,000
Closed -$1.24M
BVS icon
23
Bioventus
BVS
$1.16B
-352,569
Closed -$4.17M
COO icon
24
CALL
Cooper Companies
COO
$14.4B
-60,000
Closed -$6.62M
CSTL icon
25
Castle Biosciences
CSTL
$963M
-62,868
Closed -$1.91M

Similar funds

Pura Vida Investments's Q4 2024 Portfolio in Review

As of Q4 2024, Pura Vida Investments held 48 positions worth $31.6M, down 79% from $153M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Pura Vida Investments withdrew a net $117M in Q4 2024, closing 29 positions and reducing 11 holdings. Its most notable exit was Glaukos, an estimated $6.06M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 32% a quarter earlier.

Against the trend, Pura Vida Investments added an estimated $432K to Insight Molecular Diagnostics.

  • Pura Vida Investments added most to Insight Molecular Diagnostics in Q4 2024, an estimated $432K increase.
  • Pura Vida Investments's biggest Q4 2024 reduction was Natera, cutting an estimated $5.61M.
  • Pura Vida Investments fully exited Glaukos in Q4 2024, selling an estimated $6.06M.
  • Pura Vida Investments's ten largest holdings make up 74% of its $31.6M portfolio in Q4 2024.
  • Pura Vida Investments opened 6 new positions and closed 29 in Q4 2024.
  • Pura Vida Investments's portfolio value fell 79% quarter-over-quarter to $31.6M.

Based on Pura Vida Investments's 13F filing for Q4 2024, filed 12 Feb 2025.